title: Treatment options for hyponatremia in heart failure.
abstract: Hyponatremia is independently associated with adverse outcomes in patients with congestive heart failure (CHF). The primary cause of hyponatremia in CHF is the inappropriate secretion of the antidiuretic hormone, arginine vasopressin (AVP). The binding of AVP to V(2) receptors in the renal collecting duct promotes water retention, a process that can lead to dilutional hyponatremia as well as increased ventricular preload. AVP could also exacerbate the course of CHF by interacting with V(1A) receptors on vascular smooth muscle cells and myocytes. Conventional treatment of hyponatremia in CHF is based largely on water restriction, which is neither effective nor well tolerated. Current research is exploring V(2)- and dual V(1A)/V(2)-receptor antagonism for the treatment of hyponatremia, as well as for the congestion and edema associated with CHF, since AVP-receptor antagonists may offer benefits in comparison to conventional loop diuretics. Clinical trials in patients with hyponatremia and CHF using both selective and nonselective vasopressin antagonists have demonstrated the effectiveness of these agents in correcting this common electrolyte abnormality.
authors.affiliation: Cardiology Division, Hennepin County Medical Center, 701 Park Avenue, Minneapolis, MN 55415, USA. srg_hcmc@yahoo.com
authors.forename: Steven R
authors.initials: SR
authors.lastname: Goldsmith
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin / Q000378:metabolism*; D001381:Azepines / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D007177:Inappropriate ADH Syndrome / Q000150:complications / Q000378:metabolism; D011758:Pyrroles; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use; D000077602:Tolvaptan; D016896:Treatment Outcome; D001569:Benzodiazepines
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001127:Arginine Vasopressin; D001381:Azepines; D001549:Benzamides; D001552:Benzazepines; D011758:Pyrroles; D049994:Sodium Potassium Chloride Symporter Inhibitors; D000077602:Tolvaptan; C409452:lixivaptan; D001569:Benzodiazepines
references.citation: Rev Cardiovasc Med. 2003;4 Suppl 7:S21-30
references.pmid: 14668697
references.citation: Am J Nephrol. 2007;27(5):447-57
references.pmid: 17664863
references.citation: Cardiovasc Res. 2002 Apr;54(1):51-7
references.pmid: 12062361
references.citation: Cardiovasc Drug Rev. 2001 Fall;19(3):201-14
references.pmid: 11607038
references.citation: Kidney Int. 1986 Jun;29(6):1188-96
references.pmid: 3528612
references.citation: J Pharmacol Exp Ther. 1997 Jul;282(1):301-8
references.pmid: 9223568
references.citation: J Clin Invest. 1989 Aug;84(2):418-26
references.pmid: 2527249
references.citation: J Pharmacol Exp Ther. 1998 Dec;287(3):860-7
references.pmid: 9864265
references.citation: J Am Coll Cardiol. 2004 Sep 15;44(6):1308-10
references.pmid: 15364337
references.citation: J Am Soc Nephrol. 1999 Mar;10(3):647-63
references.pmid: 10073616
references.citation: Cardiology. 2003;100(3):136-42
references.pmid: 14631134
references.citation: Adv Exp Med Biol. 1998;449:439-43
references.pmid: 10026835
references.citation: Eur J Pharmacol. 1997 Feb 26;321(2):225-30
references.pmid: 9063692
references.citation: Eur J Pharmacol. 1999 Sep 17;381(1):23-30
references.pmid: 10528130
references.citation: N Engl J Med. 1981 Jul 30;305(5):263-6
references.pmid: 7242616
references.citation: N Engl J Med. 2006 Nov 16;355(20):2099-112
references.pmid: 17105757
references.citation: Ann Intern Med. 1985 Jul;103(1):1-6
references.pmid: 2860833
references.citation: JAMA. 2002 Mar 27;287(12):1541-7
references.pmid: 11911756
references.citation: J Clin Invest. 2004 Jan;113(2):302-9
references.pmid: 14722621
references.citation: J Am Coll Cardiol. 1986 Oct;8(4):779-83
references.pmid: 3760354
references.citation: J Cardiovasc Pharmacol. 1996 Feb;27(2):275-82
references.pmid: 8720428
references.citation: Clin Sci (Lond). 1980 Dec;59(6):443-9
references.pmid: 7002435
references.citation: J Am Coll Cardiol. 2004 Sep 15;44(6):1301-7
references.pmid: 15364336
references.citation: J Am Coll Cardiol. 2003 Aug 20;42(4):705-8
references.pmid: 12932605
references.citation: Science. 1986 Mar 28;231(4745):1572-3
references.pmid: 3006248
references.citation: Circ Res. 1991 Jul;69(1):239-45
references.pmid: 2054937
references.citation: Circulation. 1990 Nov;82(5):1724-9
references.pmid: 2146040
references.citation: J Mol Endocrinol. 2002 Aug;29(1):1-9
references.pmid: 12200224
references.citation: Hepatology. 2003 Jan;37(1):182-91
references.pmid: 12500203
references.citation: Eur J Pharmacol. 1999 Jul 9;376(3):239-46
references.pmid: 10448882
references.citation: Am Heart J. 2003 Mar;145(3):459-66
references.pmid: 12660669
references.citation: J Pharmacol Exp Ther. 2000 Jan;292(1):288-94
references.pmid: 10604960
references.citation: Clin Exp Pharmacol Physiol. 1999 May-Jun;26(5-6):399-403
references.pmid: 10386228
references.citation: Am J Med. 1999 Jan;106(1):90-6
references.pmid: 10320123
references.citation: Am J Med Sci. 2009 Jan;337(1):28-36
references.pmid: 19057376
references.citation: Circulation. 2005 May 17;111(19):2454-60
references.pmid: 15867182
references.citation: Eur J Intern Med. 2002 Aug;13(5):304-310
references.pmid: 12144909
references.citation: JAMA. 2003 Nov 19;290(19):2581-7
references.pmid: 14625335
references.citation: Am J Physiol. 1994 Dec;267(6 Pt 2):H2245-54
references.pmid: 7810724
references.citation: Circulation. 2001 Nov 13;104(20):2417-23
references.pmid: 11705818
references.citation: Eur J Pharmacol. 2000 Mar 10;391(1-2):39-48
references.pmid: 10720633
references.citation: J Card Fail. 1999 Dec;5(4):347-56
references.pmid: 10634676
references.citation: Am J Med. 2006 Jan;119(1):71.e1-8
references.pmid: 16431193
references.citation: Arch Intern Med. 1996 Sep 9;156(16):1814-20
references.pmid: 8790075
references.citation: J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52
references.pmid: 16522696
references.citation: Am J Cardiol. 1986 Aug 1;58(3):295-9
references.pmid: 3739918
references.citation: JAMA. 2004 Apr 28;291(16):1963-71
references.pmid: 15113814
references.citation: J Am Coll Cardiol. 1986 Apr;7(4):758-65
references.pmid: 3514728
references.citation: J Card Fail. 2008 Oct;14(8):641-7
references.pmid: 18926434
references.citation: Eur J Pharmacol. 2002 Aug 23;450(2):169-77
references.pmid: 12206855
references.citation: JAMA. 2007 Mar 28;297(12):1319-31
references.pmid: 17384437
references.citation: Am J Physiol Renal Physiol. 2006 Feb;290(2):F273-8
references.pmid: 16189291
references.citation: J Am Coll Cardiol. 1983 Jun;1(6):1385-90
references.pmid: 6343460
references.citation: J Clin Endocrinol Metab. 1984 Apr;58(4):599-605
references.pmid: 6365943
references.citation: Am J Med. 1982 Jan;72(1):49-52
references.pmid: 7058822
references.citation: Am J Med Sci. 2000 Jan;319(1):10-24
references.pmid: 10653441
references.citation: Am J Manag Care. 1999 Jun;5(6):715-23
references.pmid: 10538451
references.citation: J Clin Invest. 2000 Jul;106(1):107-16
references.pmid: 10880054
references.citation: Circulation. 1986 Feb;73(2):257-67
references.pmid: 3002660
references.citation: J Am Coll Cardiol. 2002 Nov 20;40(10):1801-8
references.pmid: 12446064